Lilly has a bad hair day as Pfizer rival hits the mark in alopeciaEli Lilly and Incyte have another rival in the rear-view mirror for Olumiant in alopecia areata after Pfizer Share XLilly has a bad hair day as Pfizer rival hits the mark in alopeciahttps://pharmaphorum.com/news/lilly-has-a-bad-hair-day-as-pfizer-rival-hits-the-mark-in-alopecia/
Chasing Lilly, Concert eyes 2023 filing for its JAK drug for alopeciaConcert Pharmaceuticals has started the second of two planned phase 3 trials of its drug candidate for alopecia Share XChasing Lilly, Concert eyes 2023 filing for its JAK drug for alopeciahttps://pharmaphorum.com/news/chasing-lilly-concert-eyes-2023-filing-for-its-jak-drug-for-alopecia/
PureTech unit Follica cues up phase 3 programme for male hair lossPureTech has said one of the companies it has founded – Follica – is preparing to start registration Share XPureTech unit Follica cues up phase 3 programme for male hair losshttps://pharmaphorum.com/news/puretech-unit-follica-cues-up-phase-3-programme-for-male-hair-loss/
FDA gives Lilly’s Olumiant breakthrough status for hair lossEli Lilly’s Olumiant is facing tough competition in its approved rheumatoid arthritis indication, but could take the lead Share XFDA gives Lilly’s Olumiant breakthrough status for hair losshttps://pharmaphorum.com/news/fda-gives-lillys-olumiant-breakthrough-status-for-hair-loss/
Allergan bolsters aesthetics pipeline with Exicure hair loss dealAllergan hasn’t pressed pause on business development in the build-up to its $63 billion buyout by AbbVie, and Share XAllergan bolsters aesthetics pipeline with Exicure hair loss dealhttps://pharmaphorum.com/news/allergan-bolsters-aesthetics-unit-with-exicure-hair-loss-deal/
